Summary
Persistent and transient muscular rigidities were induced by 6-aminonicotinamide (6-AN) and reserpine, respectively, in rats and recorded electromyographically.
Very low doses of lisuride (25 or 50 μg/kg) reduced or abolished the increased electromyographic activity in the gastrocnemius muscle. Similar results were obtained with the combination of L-DOPA (100 mg/kg) plus benserazide (25 mg/kg). Methysergide was inactive. It is suggested that lisuride could be of value in the therapy of Parkinson's disease.
This is a preview of subscription content, log in via an institution to check access.
References
Barbeau, A.: The pathogenesis of Parkinson's disease: A new hypothesis. Can. med. Ass. J. 87, 802–807 (1962)
Barbeau, A.: L-DOPA therapy in Parkinson's disease. A critical view of nine year's experience. Can. med. Ass. J. 101, 791–800 (1969)
Bertler, Å.: Effect of reserpine on the storage of catecholamines in brain and other tissues. Acta Physiol. Scand. 51, 75–83 (1961)
Birkmayer, W., Hornykiewicz, O.: Der L-3,4-Dioxyphenalanin-(=DOPA)-Effekt bei der Parkinson Akinese. Wien. Klin. Wochenschr. 45, 787–788 (1961)
Calne, D. B.: Parkinsonism: Physiology, pharmacology and treatment. London: B. Arnold 1970
Calne, D. B. (Ed.): Progress in the treatment of Parkinsonism. Advances in Neurology, Vol. 3. New York: Raven Press 1973
Calne, D. B., Sandler, M.: L-DOPA and Parkinsonism. Nature 226, 21–24 (1970)
Coper, H., Herken, H.: Schädigung des Zentralnervensystems durch Antimetaboliten des Nikotinamids. Dtsch. Med. Wochenschr. 42, 2025–2036 (1963)
Davidson, L., Lloyd, K., Dankova, J., Hornykiewicz, O.: L-DOPA treatment in Parkinson's disease: Effect on dopamine and related substances in discrete brain regions. Experientia 27, 1048–1049 (1971)
Goldstein, J. M., Barnett, A., Malick, J. B.: The evaluation of anti-Parkinson drugs on reserpine-induced rigidity in rats. Eur. J. Pharmacol. 33, 183–188 (1975)
Halbhübner, K., Loos, D., Herken, H.: Pharmacological and electromyographic differentiation of the neurotoxic action of 6-aminonicotinamide. Nauyn-Schmiedeberg's Arch. Pharmacol. 297, R57 (1977)
Herken, H., Keller, K., Kolbe, H., Lange, K., Schneider, H.: Experimentelle Myelopathie — Biochemische Grundlagen ihrer zellulären Pathogenese. Klin. Wochenschr 51, 644–657 (1973)
Herken, H., Meyer-Estorf, G., Halbhübner, K., Loos, D.: Spastic Paresis after 6-aminonicotinamide: Metabolic disorders in the spinal cord and electromyographically recorded changes in the hind limbs of rats. Naunyn-Schmiedeberg's Arch. Pharmacol. 293, 245–255 (1976)
Hornykiewicz, O.: Neurochemistry of Parkinsonism. In: Handbook of Neurochemistry, Vol. 7 (A. Lajtha, ed.), pp. 465–501. New York: Plenum Press 1972
Horowski, R., Wachtel, H.: Direct dopaminergic action of lisuride hydrogen-maleate, an ergot derivate, in mice. Eur. J. Pharmacol. 36, 373 (1976)
Johnson, W. J., McColl, J. D.: 6-Aminonicotinamide, a potent nicotinamide antagonist. Science 122, 834 (1955)
Jurna, I.: Striatal monoamines and reserpine and chlorpromazine rigidity. Pharmac Ther. B 2, 113–128 (1976)
Jurna, I., Lanzer, G.: Inhibition of the effect of reserpine on motor control by drugs which influence reserpine rigidity. Naunyn-Schmiedebergs Arch. Pharmak. Exp. Path. 262, 309–324 (1969)
Kehr, W.: Effect of lisuride and other ergot derivates on monaminergic mechanisms in brain. Eur. J. Pharmacol. 41, 261–273 (1977)
Morrison, A. B., Webster, R. A.: Drug-induced experimental Parkinsonism. Neuropharmacology 12, 715–724 (1973)
Pletscher, A., Bartholini, G.: Selective rise in brain dopamine by inhibition of extracerebral levodopa decarboxylation. Clin. Pharmacol. Ther. 12, 344–352 (1971)
Rinne, U. K., Sonninen, V.: A double blind study of L-DOPA treatment in Parkinson's disease. Eur. Neurol. 1, 180–191 (1968)
Roos, B.-E., Steg, G.: The effect of L-3,4-dihydroxyphenylalanin and DL-5-hydroxytryptophan on rigidity and tremor induced by reserpine, chlorpromazine and phenoxybenzamine. Life Sci. 3, 351–360 (1964)
Schneider, H.: Elektronenmikroskopische Befunde bei selektiven Läsionen der spinalen grauen Substanz. Untersuchungen am Modell der 6-Aminonikotinamid-Intoxikation und der temporären Ischämie. Habilitationsschr., FB klin.-theor. Med. Freie Univ. Berlin 1971
Steg, G.: Efferent muscle innervation and rigidity. Acta Physiol. Scand. 61, Suppl., 225 (1964)
Sternberg, S. S., Philips, F. S.: 6-Aminonicotinamide and acute degenerative changes in the central nervous system. Science 127, 644–646 (1958)
Votava, Z., Lamplová, I.: Antiserotonin activity of some ergolenyl and isoergolenyl derivates in comparison with LSD and the influence of monoamine inhibition on this antiserotonin effect. In: Neuropsychopharmacology, Vol. 2 (E. Rothlin, ed.), pp. 68–73. Amsterdam: Elsevier, 1961
Wiesendanger, M.: Pathophysiology of muscle tone. Schriftenreihe Neurologie 9, Berlin-Heidelberg-New York: Springer 1972
Wolf, A., Cowen, D.: Pathological changes in the central nervous system produced by 6-aminonicotinamide. Bull. N.Y. Acad. Med. 35, 814–817 (1959)
Author information
Authors and Affiliations
Additional information
N-(D-6-methyl-8-isoergolenyl)-N′,N′-diethylcarbamide hydrogen maleate
Rights and permissions
About this article
Cite this article
Loos, D., Halbhübner, K. & Herken, H. Lisuride, a potent drug in the treatment of muscular rigidity in rats. Naunyn-Schmiedeberg's Arch. Pharmacol. 300, 195–198 (1977). https://doi.org/10.1007/BF00505052
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00505052